Prof Ehrlich - Abivax SA Chief Officer

All Insiders . France . 
Stock . Abivax SA . Stakeholders . Insider . Prof Ehrlich
ABVX Stock  EUR 8.44  0.24  2.93%   

Insider

Prof Ehrlich is Chief Officer of Abivax SA
Phone33 1 53 83 08 41
Webhttps://www.abivax.com

Abivax SA Management Efficiency

The company has return on total asset (ROA) of (0.4368) % which means that it has lost $0.4368 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (12.8647) %, meaning that it generated substantial loss on money invested by shareholders. Abivax SA's management efficiency ratios could be used to measure how well Abivax SA manages its routine affairs as well as how well it operates its assets and liabilities.
Abivax SA has accumulated 53.45 M in total debt with debt to equity ratio (D/E) of 31.4, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Abivax SA has a current ratio of 2.16, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Abivax SA until it has trouble settling it off, either with new capital or with free cash flow. So, Abivax SA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Abivax SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Abivax to invest in growth at high rates of return. When we think about Abivax SA's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Valerie HanoteEurofins Scientific SE
57
Sandra HoeylaertsEurofins Scientific SE
N/A
Delphine VayletSEB SA
53
Martin ZouharSEB SA
N/A
Giles PelissierSEB SA
N/A
Timothy OostdykEurofins Scientific SE
N/A
Gabriel JuliaEurofins Scientific SE
N/A
Heiko ImhlSartorius Stedim Biotech
N/A
Cathy PianonSEB SA
N/A
Philippe SchailleeSEB SA
N/A
Valerie LeyldeBiomerieux SA
N/A
Mark MillerBiomerieux SA
N/A
Pierre CharbonnierBiomerieux SA
N/A
Alexandre MerieuxBiomerieux SA
49
Rajesh SaigalEurofins Scientific SE
N/A
Olivier GuitardSartorius Stedim Biotech
N/A
Stanislas GramontSEB SA
57
Laurent LebrasEurofins Scientific SE
N/A
Gilles MartinEurofins Scientific SE
60
Joachim KreuzburgSartorius Stedim Biotech
58
Guillaume BouhoursBiomerieux SA
47
ABIVAX Socit Anonyme, a biotechnology company, develops, markets, and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious diseases in Asia and Latin America. The company was incorporated in 2013 and is headquartered in Paris, France. ABIVAX is traded on Paris Stock Exchange in France. Abivax SA (ABVX) is traded on Euronext Paris in France and employs 24 people.

Management Performance

Return On Equity-12.86
Return On Asset-0.44

Abivax SA Leadership Team

Elected by the shareholders, the Abivax SA's board of directors comprises two types of representatives: Abivax SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Abivax. The board's role is to monitor Abivax SA's management team and ensure that shareholders' interests are well served. Abivax SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Abivax SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Didier Blondel, CFO, Board Secretary
Alain Chevallier, Advisor
Philippe MD, Founder Director
Regina Jehle, VP Communications
Prof Ehrlich, Chief Officer
Paul Gineste, VP Operations
Anne Pascard, HR Mang
Raquel Lizarraga, Investor Mang
Pierre MBA, Chief Devel
Alexandra Pearce, Vice President and Head of Regulatory Affairs

Abivax Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Abivax SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-12.86
Return On Asset-0.44
Operating Margin4.66 %
Current Valuation157.22 M
Shares Outstanding42.32 M
Shares Owned By Insiders2.46 %
Shares Owned By Institutions30.18 %
Price To Earning(7.59) X
Price To Book22.19 X
Price To Sales3,840 X

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
RSIRush Street Interactive
OKTAOkta Inc
BACBank of America

Other Information on Investing in Abivax Stock

Abivax SA financial ratios help investors to determine whether Abivax Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Abivax with respect to the benefits of owning Abivax SA security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY